The specific and selective AT2R agonist, C21 (Ki: 0.4 nM), was provided by Vicore Pharma AB (Göteborg, Sweden). Nitric oxide synthase inhibitor, N(ω)-nitro-L-arginine methyl ester (L-NAME), was purchased from Sigma Aldrich Co. (St. Louis, United States). The AT1R antagonist, candesartan, and alpha (α)2-adrenergic receptor agonist, clonidine, were purchased from Tocris Bioscience (Bristol, United Kingdom). Perfusion doses of C21, L-NAME, candesartan and clonidine were based on previous studies (Ogawa et al., 1995 (link); Yang et al., 2005 (link); Mertens et al., 2011 (link); Brouwers et al., 2015 (link)).
Free full text: Click here
